Detalhe da pesquisa
1.
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
Ann Hematol
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568260
2.
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Br J Haematol
; 199(4): 529-538, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36089912
3.
Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognostic factor.
Dermatol Ther
; 33(6): e14428, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33073453
4.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Ann Hematol
; 98(2): 321-330, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446802
5.
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Ann Hematol
; 97(11): 2089-2098, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29955943
6.
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Haematologica
; 102(1): 103-109, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686377
7.
Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.
Ann Hematol
; 96(1): 81-85, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717993
8.
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Blood
; 123(4): 494-500, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24311723
9.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Blood
; 122(6): 872-84, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23803709
10.
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Am J Hematol
; 90(4): E66-72, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25580915
11.
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Am J Hematol
; 90(5): 429-33, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683327
12.
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Blood
; 119(25): 5963-71, 2012 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22508936
13.
Paroxysmal nocturnal hemoglobinuria: a single Spanish center's experience over the last 40 yr.
Eur J Haematol
; 93(4): 309-19, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24758317
14.
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Am J Hematol
; 89(11): E206-11, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25059397
15.
Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.
J Cutan Pathol
; 41(5): 417-26, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24467724
16.
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.
Am J Dermatopathol
; 36(7): 592-3, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23612033
17.
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Hemasphere
; 7(1): e818, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36570691
18.
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
Biochem Pharmacol
; 182: 114203, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32828803
19.
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
J Clin Med
; 10(1)2020 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33375572
20.
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
J Mol Diagn
; 22(10): 1217-1224, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32688056